OSLO - 16th of January 2024: 

Reference is made to SoftOx (the Company) press release of 11th and 16th January
2024 where the Company announced on-going work to restructure the financial
situation.
The Company hereby announces that we have closed a conditional agreement with
the lender in the NOK 40 million convertible loan with the due date of 15th of
January 2024 to convert the debt plus accrued interests to equity in the Company
within 1st of April, 2024. The terms for the agreement require that the Company
successfully raise at least 25 MNOK in new share capital and the lenders in the
15 million loan plus accrued interests from spring 2023 with due date of 31.
January 2024 agrees to similar conversion. 
Total convertible debt including accrued interests and debt to employees of the
Borrower amounts to about NOK 77 million, which will all be convertible at the
same price as the price in the equity issue.

SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: (+47) 977 50 071 (Chairman of the Board Geir Almås)
About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Medtech and
clinical-stage pharmaceutical company based in Oslo, Norway, with the goal of
reducing
the spread of infection and emergence of antimicrobial resistance.
For more information on SoftOx, visit www.soft-ox.com